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Edited by S. KowalczykowskiAbstractType II topoisomerases are required for the management of DNA superhelicity and chromosome segregation,
and serve as frontline targets for a variety of small-molecule therapeutics. To better understand how these
enzymes act in both contexts, we determined the 2.9‐Å‐resolution structure of the DNA cleavage core of
human topoisomerase IIα (TOP2A) bound to a doubly nicked, 30‐bp duplex oligonucleotide. In accord with
prior biochemical and structural studies, TOP2A significantly bends its DNA substrate using a bipartite,
nucleolytic center formed at an N-terminal dimerization interface of the cleavage core. However, the protein
also adopts a global conformation in which the second of its two inter-protomer contact points, one at the
C-terminus, has separated. This finding, together with comparative structural analyses, reveals that the principal
site of DNA engagement undergoes highly quantized conformational transitions between distinct binding,
cleavage, and drug-inhibited states that correlate with the control of subunit–subunit interactions. Additional
consideration of our TOP2A model in light of an etoposide-inhibited complex of human topoisomerase IIβ
(TOP2B) suggests possible modification points for developing paralog-specific inhibitors to overcome the
tendency of topoisomerase II-targeting chemotherapeutics to generate secondary malignancies.
© 2012 Elsevier Ltd.Open access under CC BY-NC-ND license.Introduction
Topoisomerases are essential enzymes that
manage the higher-order structural state of DNA.
By selectively cleaving, rearranging, and religating
DNA strands, topoisomerases can both alter the
superhelical state of DNA and help disentangle
interlinked chromosomes.1 Topoisomerases fall into
two general categories, termed type I or type II,
depending on whether one or both DNA strands of a
single duplex are cut during a catalytic cycle,
respectively. Although necessary for activity, the
DNA breaks generated by topoisomerases can be
subverted to give rise to mutagenic or cytotoxic
lesions.2 A variety of small-molecule agents capa-0022-2836/© 2012 Elsevier Ltd.Open access under CC BY-NC-ND liceble of inducing such effects have been identified to
date, many of which serve as frontline antibiotics or
anticancer agents.3
Type II topoisomerases operate by a complex
mechanism that involves the controlled associa-
tion and dissociation of subunit dimerization
elements.4–8 In this reaction, one DNA duplex
(termed the “G-segment”) is bound and cleaved by
the enzyme, while a second double-stranded DNA
(the “T-segment”) is transported through the break.
G-segment breakage is catalyzed by a pair of
symmetrically related tyrosines9–11 forming a tran-
sient, but covalently linked, topoisomerase∙DNA
assembly termed the cleavage complex. Strand
passage is typically dependent upon ATP,12–15 aJ. Mol. Biol. (2012) 424, 109–124nse.
110 Structure of DNA‐Bound Human TOP2Acofactor that not only promotes T-segment capture
and stimulates G-segment cleavage but also triggers
the successive opening and closing of inter-protomer
interfaces, or “gates”.4–6,16–19 Type IIA topoisome-
rases, which comprise one of two type II topoisom-
erase subfamilies found predominantly in bacteria
and eukaryotes,20 possess three such regions,
termed the N-gate, DNA-gate, and C-gate.1,21
Although a general structural framework for type IIA
topoisomerase action has been established for some
time,22 manymechanistic questions, such as the role
of metal ions in DNA cleavage, or how specific
catalytic events are coordinated with gate actuation,
remain ill defined.
Humans express two type IIA topoisomerase
paralogs, or isoforms, termed topoisomerase IIα
(TOP2A)23 and topoisomerase IIβ (TOP2B).24,25
Type IIA topoisomerases share significant amino
acid sequence homology between species, with the
human type II topoisomerases being ~ 40% identical
with Saccharomyces cerevisiae topoisomerase II
(Top2) (Fig. S1). Overall, the two human enzymes
are 68% identical with each other,26 with the
catalytic portions of the proteins sharing ~ 78%
identity. TOP2A and TOP2B have different expres-
sion patterns in mouse,27 with TOP2A produced in
proliferating tissues and TOP2B expressed more
systemically. Expression of both isoforms are cell
cycle dependent; levels for both are highest in
dividing cells, but TOP2B is the predominant paralog
in non-dividing and post-mitotic cells.28–31 In gener-
al, TOP2A plays a more central role in chromosome
segregation and DNA replication,32,33 whereas
TOP2B seems to be involved primarily in transcrip-
tional regulation.34–36
Due to its role in cell proliferation, TOP2A expres-
sion has been used as a cancer cell marker.37–40 Both
human type II topoisomerases are targets of highly
effective anticancer drugs such as epipodophyllotox-
ins (e.g., etoposide); however, in some human
patients, these agents also increase the likelihood of
therapy-related malignancies, such as acute myeloid
leukemia.41–43 Several studies have suggested that
these secondary cancers may be linked to the
undesired action of such drugs on TOP2B,44–47
raising the possibility that TOP2A-specific inhibitors
(e.g., NK31448) might be useful for improving thera-
peutic outcomes. One challenge to identifying such
compounds arises from the fact that the principal drug-
binding locus, the DNA-gate, is one of the most highly
conserved regions between the two enzymes. Struc-
tural insights from both drug-bound and drug-free
states of DNA-bound TOP2A and TOP2B complexes
are ultimately needed to aid efforts aimed at improving
specificity. Currently, only an etoposide-inhibited form
of the human TOP2B DNA cleavage core has been
imaged crystallographically.49
To better understand both the type IIA topoisom-
erase mechanism and to identify features that candistinguish between closely related epipodophyllo-
toxin-binding sites, we have crystallized and solved
the structure of the central catalytic region of human
TOP2A bound noncovalently to a doubly nicked
DNA substrate. The complex not only exhibits the
now-canonical DNA bend imparted by type IIA
topoisomerase family members49–55 but also fos-
ters comparative studies that provide new insights
into how the relative configuration of the active site
for DNA cleavage correlates with both metal-ion
occupancy and the opening and closing of a distal
C-terminal dimer interface. Analysis of the TOP2A
structure in light of the etoposide-inhibited state of
human TOP2B confirms the close relationship
between the two isoforms that favors inhibitor
cross-reactivity, while also highlighting two positions
in the drug-binding pocket that could serve as
differentiating features for developing more selec-
tive anti-topoisomerase agents.
Results and Discussion
Overview of the human TOP2A–DNA complex
As no structure of the human TOP2A DNA binding
and cleavage core had been determined previously,
we used sequence homology and existing type IIA
topoisomerase structures as a guide for constructing
a minimal, crystallizable fragment (residues 431–
1193, Fig. 1a). This protein was expressed and
purified (Materials and Methods) and subsequently
co-crystallized with a duplex DNA 13mer containing
complementary four-base, 5′ overhangs (Fig. 1b).
Following data collection and phasing by molecular
replacement (Materials and Methods), the resultant
electron density maps readily permitted modeling of
the entire DNA substrate and essentially all of the
protein (Fig. 2a and b). The final model was refined
to 2.9 Å resolution with an Rwork/Rfree of 22.7%/
27.0% and excellent stereochemistry (Table 1).
The TOP2A∙DNA complex forms a homodimer
(Fig. 2c), in which the two protomers derive from a
pair of asymmetric units related by crystal symmetry.
One DNA oligo associates with each protomer,
forming a doubly nicked, pseudo-continuous duplex
in which the complementary overhangs pair with one
another across the molecular dyad. Dimerization at
the site of DNA binding (corresponding to the DNA-
gate) buries 2560 Å2 of surface area between three
elements—ametal-ion binding TOPRIM (TOpoisom-
erase/PRIMase) domain, a winged-helix domain
(WHD) bearing the active-site tyrosine, and the
“tower” domain—which reside on both halves of the
dimer (Figs. 1a and 2c). Two isoleucines, one on
each protomer (Ile856), intercalate into the minor
groove of DNA, together bending the duplex by 130°;
additional DNA contacts are manifest by numerous
nonspecific, electrostatic interactions within the large
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Fig. 1. Crystallization constructs.
(a) Primary structure of human
TOP2A. The region crystallized (res-
idues 431–1193) is shown in color.
Specific domains (TOPRIM, WHD,
tower) and dimerization gates are
labeled with important residues and
features highlighted: catalytic tyro-
sine and associated arginine, RY;
intercalating isoleucine, I; metal-
binding triad, DxD and E. (b) Sche-
matic of the doubly nicked, 30‐bp
DNA substrate. Nicks and intercala-
tion sites are highlighted.
111Structure of DNA‐Bound Human TOP2A(~ 3130 Å2), positively charged DNA-binding sur-
face of the protein. The degree of bending seen in
the structure coincides with that reported for TOP2A
by fluorescence resonance energy transfer (136 ±
17°)55 and with structures of other type IIA topoi-
somerase∙DNA complexes.50,52,53,57
Within each protomer, a cluster of invariant amino
acids forms the active site for DNA cleavage
(Fig. 2a). The catalytic tyrosine (Tyr805), responsible
for nucleophilic attack on the DNA, resides ~ 6 Å
from the backbone, opposite the nick; the two
aspartates (Asp541 and Asp543) that form the
conserved DxD motif of the TOPRIM region sit
nearby, coordinating a single Mg2+. A third invariant
acidic moiety of the TOPRIM domain, Glu461,
hydrogen bonds to the 3′ OH of the DNA strand,
while Arg804, which ligands the scissile phosphate
in covalent cleavage complexes determined for type
IIA topoisomerases, coordinates the − 1 phosphate
in this structure. In general, these contacts comport
well with the active-site environments seen in other
structures of type IIA topoisomerases complexed
with DNA.49–53,57,58
Implications for inhibition of TOP2A by
exogenous agents
Type IIA topoisomerases are targets of both
small-molecule inhibitors and posttranslational reg-
ulatory events that can alter enzyme activity. The
structure of the TOP2A∙DNA complex affords a new
understanding of two such strategies. One is
SUMOylation, which recently has emerged as an
important, albeit poorly understood, modification of
topo II.59,60 Most posttranslational modification
sites, SUMOylation loci included,61 reside in the
highly divergent C-terminal region of eukaryotictype IIA topoisomerases. However, a recent study
found that a catalytic core residue, Lys660 of
Xenopus laevis TOP2A, could be SUMOylated by
Protein Inhibitor of Activated STAT-gamma
(PIASγ), resulting in loss of decatenation activity.62
In human TOP2A, this residue (Lys662) is directly
involved in binding G-segment DNA (Fig. S2). This
contact indicates that SUMOylation likely inhibits
TOP2A by interfering with G-segment binding or by
preventing the TOPRIM domain from properly
forming a functional DNA-gate. Curiously, SUMOy-
lation of Xenopus TOP2A in vitro was observed
only in the presence of DNA, even though the
reactive lysine is buried in the DNA binding
interface. Moreover, Lys662 does not reside in a
typical ϕ-K-X-E/D SUMOylation target motif (where
ϕ is a hydrophobic residue) recognized by the
Xenopus or human enzyme.63,64 These peculiari-
ties suggest that PIASγ may be SUMOylating
Lys662 in an unusual fashion, perhaps capturing
a state of the enzyme where the G-segment binding
site has undergone a marked rearrangement from
the conformations seen crystallographically.
Our TOP2A model also provides useful insights
into epipodophyllotoxin inhibition, particularly with
respect to efforts aimed at engineering compounds
that discriminate between the two human isoforms. A
recent landmark structure of human TOP2B in
complex with etoposide establishes the binding
pocket and modality for this class of topoisomerase
II poisons.49 This pocket is solvent accessible in our
TOP2A structure, but insufficiently large to accom-
modate drug. In TOP2B, the expanded pocket
derives from changes in global protein conformation:
association of the relatively nonplanar compound
alters the disposition of the two WHDs in the dimer
interface with respect to each other, deforming the
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Fig. 2. Structure of the human TOP2A DNA binding and cleavage core bound to DNA. (a) Refined 2Fo − Fc map around
the nucleolytic center (1.4 σ contour). The active site is formed around DNA (yellow) at the interface between the TOPRIM
domain (cyan) andWHD (magenta) of opposing protomers. (b) Refined 2Fo − Fc electron density map (2 σ contour) clearly
shows the bound DNA substrate. (c) The human TOP2A∙DNA complex as viewed from the front (left) and above (right).
Domains are colored as in Fig. 1a, with DNA in dark orange. The G-segment is bound in the DNA-gate, and the C-gate
dimerization interface is dissociated.
112 Structure of DNA‐Bound Human TOP2ADNA and pushing each TOPRIM domain away from
the WHD of its partner protomer. These observed
structural changes comprise rigid-body, en bloc
movements between the WHDs and TOPRIM
domains in the dimer, suggesting that following
DNA cleavage, drug binding occurs during transient
opening or breathing of the DNA-gate.
To investigate how etoposide might interact with
human TOP2A, we individually superposed both the
WHD and TOPRIM domain from our structure onto
that of TOP2B. A single superposition using both
domains simultaneously was not feasible due to the
aforementioned conformational changes in the
region (Fig. 3a); however, the backbones of both
domains individually align well with those of TOP2B
(WHD Cα RMSD = 0.70 Å, TOPRIM Cα RMSD =
0.51 Å). Of the four TOP2B residues that make side-chain contacts with the drug, the only residue that is
different in the corresponding TOP2A binding site is
the substitution of a methionine (Met762) for
glutamine (Gln778 in TOP2B) (Fig. 3b and c). The
sulfur atom in methionine is unlikely to participate in
the hydrogen-bonding interaction seen to occur
between the glutamine amide of TOP2B and the
O12 moiety on the “D” ring of etoposide. Neverthe-
less, etoposide is known to act in vitro against both
human paralogs65 and targets both proteins in
cells.66,67 Since Gln778 adopts two conformations
in the TOP2B structure,49 its observed contacts with
etoposide likely are not crucial for inhibitor activity.
A comparison of the two structures suggests a
few possible avenues by which etoposide might be
modified to better discriminate between TOP2A and
TOP2B. Adding different substituents to the lactone
Table 1. Diffraction and refinement statistics for the DNA‐
bound human TOP2A complex
Structure
Human topo
IIα–DNA complex
Space group C2221
Unit cell dimensions
a, b, c (Ǻ) 85.91, 215.08, 128.65
α, β, γ (°) 90, 90, 90
Data collection
Wavelength (Å) 1.1159
Resolution (highest shell) 49.6–2.9 (3.00–2.90)
Observed reflections 552,602
Unique reflections 25,373
Rsym (%) (3.00–2.90 Å)
a 9.3 (71.2)
I/σI (3.00–2.90 Å) 15.4 (2.0)
Completeness (3.00–2.90 Å) 95.3 (91.6)
Redundancy (3.00–2.90 Å) 7.2 (4.5)
Refinement
Rwork
b (%) 22.7
Rfree
b (%) 27.0
Reflections in test set (% of total) 1285 (5.1)
No. of atoms
Protein/DNA 6538
Solvent 44
Average B‐factor (Å2)
Protein/DNA 80.2
Solvent 37.6
Bond length deviations from ideal (Å) 0.006
Bond angle deviations from ideal (°) 0.847
Ramachandran outliersc (%) 0
Ramachandran favoredc (%) 96.4
a Rsym =∑|I − Iσ|/∑I, where I is the integrated intensity for a
given reflection.
b Rwork =∑|Fo − Fc|/∑Fo, where Fo and Fc are the observed and
calculated structure factor amplitudes, respectively. Rfree is
calculated as for Rwork, but from a subset of the data (5.1%) that
was withheld from crystallographic refinement.
c As defined by MolProbity.56
113Structure of DNA‐Bound Human TOP2Agroup of etoposide to take advantage of the different
chemistries, steric bulk, and rotamer preferences
of glutamine versus methionine could constitute
one approach. The reactivity of methionine might
also be exploited, for instance, through platinum
conjugates,68,69 to select for TOP2A reactivity. Our
modeling suggests that the glycosidic moiety on the
etoposide “C” ring is another possible candidate for
modification (Fig. 3c). In the TOP2B complex, this
group resides within a large binding pocket on the
enzyme but makes few contacts with the protein
surface. NMR studies have corroborated this paucity
of contacts,70 and removal of the sugar is known to
cause little change in drug activity in vitro.70,71
Comparison of this region between human TOP2A
and TOP2B reveals a single point difference between
the two isoforms, with Ser800 of TOP2A replacing
Ala816 of TOP2B (Fig. 3c). This substitution suggests
that the addition of a hydrogen-bonding or serine-
reactive extension to the 8″ carbon position of the
glycosidic group of etoposide might be useful for
increasing TOP2A selectivity. Interestingly, tenipo-side, an etoposide analog that shows a fourfold
greater inhibitor effect against TOP2A as compared
with TOP2B in vitro,72 may already employ such an
approach: teniposide possesses a thienyl sulfur in
lieu of the methyl group found on etoposide's
glycosidic C-ring, which modeling suggests could
make van der Waals contacts with Ser800.
Distinguishing features between TOP2A and
other eukaryotic type II topoisomerases
Outside of the active site, various structures have
captured a range of conformational states for the
DNA binding and cleavage core of type IIA topoi-
somerases as a whole. Our present TOP2A model
bears greatest resemblance to a noncovalent
complex between a doubly nicked, duplex DNA
and the corresponding region of S. cerevisiae
topoisomerase II (Fig. 4a).50 Both models retain a
closed DNA-gate and exhibit similar DNA-bend
angles and catalytic-tyrosine positions relative to
the DNA backbone. More strikingly, the C-terminal
dimerization interface that regulates DNA transport
through type IIA topoisomerases (the “C-gate”) is
separated in both structures.
Aside from single amino acid substitutions, the
most significant differences between human TOP2A
and yeast Top2 map to two regions of secondary
structure. One is an insertion in helix α11 (residues
670–686 of human TOP2A, Fig. S1) of the three-
helix bundle that both connects the TOPRIM domain
to the WHD and forms part of the DNA binding
interface (Fig. 4b). This insertion packs against a
flexible “Greek-key” element, which constitutes a
distinct augmentation to the TOPRIM fold of type IIA
topoisomerases, pinning this subdomain against the
WHD of the partner subunit. The second difference
maps to the C-gate (Fig. 4c), where a short α-helix
in human TOP2A (residues 1086–1092) replaces a
β-hairpin in the yeast model, thereby forming an
interface with one of the two long α-helical arms
(residues 1015–1060) that extend from the DNA-
gate. The functional significance of these modifica-
tions, if any, is not known at present.
By contrast to these respective similarities and
differences with yeast Top2, the human TOP2A∙DNA
complex is more akin to human TOP2B in terms of
local structure, but distinct insofar as global confor-
mation. Like TOP2A, TOP2B contains the extended
helix in the three-helix bundle between the TOPRIM
and WHD, as well as the extra helix near the C-gate.
However, the TOPRIM-associated Greek-key domain
is not visible in the TOP2B structure, despite the high
resolution of the model (2.2 Å).49 This element may
be disordered in TOP2B due to natural substitutions
of Tyr684 for phenylalanine and Thr689 for alanine,
which together would abrogate interactions between
the α11 extension and the Greek-key motif seen in
TOP2A (Fig. 4b). Alternatively, this subdomain may
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Fig. 3. Comparison of TOP2A and etoposide-bound TOP2B. (a) The global conformation of TOP2A and TOP2B differs.
Superposition of the two human isoforms shows that the TOPRIM domain in the etoposide-bound TOP2B cleavage
complex (PDB ID 3QX3) is rotated relative to the WHD and tower domain in the TOP2A structure (left panel, only one
protomer shown). The dimeric TOP2B cleavage complex has a closed C-gate compared to TOP2A (right panel). (b)
Structure and ring numbering of etoposide. (c) Only two amino acids differ in the etoposide-binding pocket of TOP2A and
TOP2B. The WHD and TOPRIM of TOP2A (cyan sticks and colored surface) are shown individually superposed on the
TOP2B (salmon sticks) drug-binding site. Two residues that differ—Met762 in TOP2A versus Gln778 in TOP2B, and
Ser800 versus Ala816—are labeled, as are three amino acids that are preserved (Arg487/503, Asp463/479, and Met766/
782). Etoposide is shown as gray/red sticks; the additional thienyl group of the related anticancer drug teniposide is
modeled in magenta to show its relation to the Ser800/Ala816 region.
114 Structure of DNA‐Bound Human TOP2Abecome disordered due to conformational differences
in the DNA-gate between the two enzymes. In
particular, in accommodating etoposide, the TOPRIM
domain of TOP2B is rotated by ~7° toward the dimer
interface compared to TOP2A (Fig. 3a), concomitant
with a lateral displacement of ~ 3 Å between its dyad-
relatedWHDs. This movement leads the DNA-gate to
crack open, decreasing the buried surface area in this
region of TOP2B by ~2000 Å2. Even more strikingly,
the C-gate of TOP2B is fully dimerized, compared to
the separated, or “open”, state seen in TOP2A
(Fig. 3a).
Inter-subunit conformational states correlate
with DNA cleavage status
The TOP2A∙DNA complex presented here joins a
growing number of structures for the DNA binding andcleavage core of type IIA topoisomerases. This
collection in turn provides a wealth of data for
comparative analyses. While considering our TOP2A
model in light of these related systems, we noted that
the majority of structures (22 out of 25) retained an
associated, or “closed”, C-gate.22,49,51–53,57,58,73–78
However, three completely distinct complexes—S.
cerevisiae Top2,50 Acinetobacter baumannii topo-
isomerase IV,52 and human TOP2A (the present
study)—have also been obtained in which the C-gate
interface is dissociated. The existence of multiple
models that derive from different topoisomerase
homologs and crystal packing environments, yet still
exhibit an “open” C-gate, strongly argues against
suggestions that this conformation represents a non-
physiologic state.51
The factors that control C-gate status have been
the subject of debate. One proposal has suggested
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Fig. 4. Comparison of TOP2A and S cerevisiae topoisomerase II. (a) The quaternary conformation of the human
TOP2A∙DNA complex most closely resembles the yeast Top2–DNA complex with a doubly nicked substrate. Architectural
differences between the two structures are most pronounced in the Greek key motif and in the C-gate (boxed regions). (b)
Differences in the TOPRIM insert region. A tyrosine (Tyr684) in the 670–686 insert of TOP2A forms hydrogen bonds with
Glu597 in the Greek key element of the TOPRIM domain. Interactions seen in TOP2A, but not yeast topoisomerase II, are
shown as sticks/broken lines and labeled. (c) Differences in the C-gate. A β-hairpin in the yeast topoisomerase II C-gate is
replaced by an α‐helix (A′α15′) in TOP2A.
115Structure of DNA‐Bound Human TOP2Athat the formation of a covalent protein∙DNA cleav-
age complex favors C-gate association, whereas
G-segment binding alone promotes (but does not
strictly enforce) C-gate opening.53 Support for this
argument centers on the existence of a physical
linkage between the active-site tyrosine and the
α-helical arms that extend into the C-terminal
interface (α14 and α18 in human TOP2A); this
connection would appear to allow DNA-gate move-
ments, triggered by entry into a cleavage-competent
conformational state, to lever the arms toward each
other and shut the gate. By contrast, the imaging of
certain noncovalent, DNA-bound type IIA topoisome-
rases with a closed C-gate57,58 has raised the
possibility that an alternative mechanism may ac-
count for the opening of this region. Entrapment of the
T-segment in the cavity between the DNA-gate and
C-gate could constitute one such approach.79
A close inspection between all 22 published type
IIA topoisomerase structures bearing a closed DNA-
gate helps resolve this question.49–53,57,58,73,76–78 In
particular, superposition between theWHDs of these
models reveals that the DNA-gate samples only a
limited number of conformational states as the
region engages a duplex substrate. For example,
in comparing apo and substrate-bound forms, the
presence of DNA correlates with a single, quantized
sliding motion of the WHDs with respect to each
other, along a vector that is both perpendicular to the
dyad axis of the topoisomerase dimer and roughly
parallel with the axes of the two α-helices that abut
each other at the dimer interface (α3 in bacterial
GyrA, and A′α3 in eukaryotic topo II) (Fig. 5a and b).
This movement corresponds to a translational shift of
the helix–turn–helix motif of each WHD past each
other by a distance corresponding to single helicalturn, clamping the TOPRIM and tower domains
around the G-segment DNA. Interestingly, the
etoposide-bound TOP2B∙DNA structure exhibits an
analogous shift of two helical turns, along with a
rotational reorientation of the TOPRIM domain
(Fig. 5b), as its DNA-gate cracks open.
The relative rotational status of the two WHDs and
their associated active-site tyrosines is similarly
quantized and correlates with both DNA cleavage
status and the dimerization state of the C-gate
(Fig. 5a and c). An open C-gate is observed only at
one end of the rotational range, which is populated
by two noncovalent topoisomerase∙DNA complexes,
as well as one apoenzyme structure.50,52 By
contrast, all other apo and DNA-bound complexes
occupy a distinct set of alternate WHD∙WHD
juxtapositions that coincide with C-gate closure.
For instance, all DNA-cleavage complexes stabi-
lized by small-molecule poisons not only have an
associated C-gate but also exhibit a consistent
counterclockwise rotation of the two WHDs with
respect to each other.51,52,57,58 This conformational
change is preserved in the etoposide-inhibited
structure between DNA and human TOP2B,49
where an extra translational shift between WHDs
has also occurred (Fig. 5b). A less-extreme, but
still evident, counterclockwise movement is seen
in every DNA-free structure that displays a closed
C-gate73,77,78 and in an S. cerevisiae Top2 cleavage
complex that was obtained using a phosphorothio-
lated suicide substrate.53
Overall, in instances where DNA is present, these
comparisons reveal a tight correlation between a
relative movement on the part of the WHDs to elicit
DNA cleavage, and the predisposition of the C-gate
to be closed. Indeed, out of the 15 topoisomerase
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117Structure of DNA‐Bound Human TOP2AII∙DNA co-crystal structures in the database, only 2
appear to run counter to this correspondence.
However, a closer consideration of these outliers
(which represent noncovalent, DNA-bound states)
demonstrates that neither structure in fact violates
the dependence of C-gate dimerization on DNA-gate
status proposed above: both structures actually
derive from topoisomerase/DNA complexes that
were exposed to a small-molecule agent that in-
terferes with the normal cleavage cycle of the
enzyme. In one example, the cleavage core of
Staphylococcus aureus gyrase was co-crystallized
with an intact DNA duplex and a non-intercalative
inhibitor of strand scission (GSK299943). Interest-
ingly, this inhibitor binds at the interface between the
two apposed WHDs, in a pocket that materializes
when the domains adopt a cleavage-like orientation
relative to each other.58 This concurrence suggests
that GSK299943 traps the DNA-gate of bacterial
type IIA topoisomerases in a conformation similar to
that adopted after the action of fluoroquinolone
poisons, which are known to impede normal
phosphotransfer chemistry.51,52,57,58 In the other
instance, the core region of Streptococcus pneumo-
niae topo IV was first crystallized with the dione PD
0305970 to stabilize a cleavage complex, after which
religation was promoted in situ by first soaking out
the drug in the presence of ethylenediaminetetraa-
cetic acid (EDTA) and then resoaking the crystals
with Mg2+.57 Thus, this latter structure derives from
a state in which the topoisomerase∙DNA complex
had already been captured with a rotated WHD
configuration and closed C-gate. An inspection of
the contacts arising from the crystal lattice indicates
that molecular packing interactions would prevent
subsequent WHD/WHD rearrangements or C-gate
opening upon removal of the drug.Fig. 5. Substrate-dependent movements in the type IIA topo
superposition of 22 type IIA topoisomerase structures, aligne
displacements of its partner WHD. The juxtapositions fall into si
two WHDs; surface representations of TOP2A are provided fo
DNA bound, C-gate open [A. baumannii topo IV (2XKJ)]; (2
(3NUH), also E. coli gyrase (1AB4), M. tuberculosis gyrase (3
TOP2A (4FM9), also S. cerevisiae topoisomerase II (2RGR)];
topoisomerase II (3L4K)]; (5) DNA cleavage complex, C-gate
topo IV bound to moxifloxacin (2XKK), also S. pneumoniae t
clinafloxacin (3FOE), levofloxacin (3K9F), a dione inhibitor (3L
and the EDTA‐soaked complex resealed by a MgCl2 soak (3K
GSK299943 (2XCR, 2XCS) and cleavage complex bound to
cleavage complex, C-gate closed, etoposide bound [huma
demarcation in relative WHD rotation angles between open an
demarcation of lateral WHD displacement between DNA‐boun
opposing protomers to slide past each other by one helical turn
IIs). This sliding can be quantized into juxtapositions taken
juxtapositions taken by DNA‐bound enzymes [conformations
etoposide‐bound TOP2B complex where the DNA-gate inter
cleavage and C-gate dimerization are correlated to a rocking o
into juxtapositions with an open C-gate and noncovalently boun
covalently bound DNA [conformations 2 and 4 in (a)], and a
[conformations 5 and 6 in (a)].These findings have additional intriguing implica-
tions for the mechanism of DNA cleavage. Based on
biochemical data, there is a general consensus that
type IIA topoisomerases rely on two metal ions for
DNA cleavage.80–82 Crystallographic efforts have
refined this picture to suggest that only one metal ion
(metal A) actively assists with the chemistry of strand
scission and religation, whereas the other (metal B)
serves a more structural role, anchoring the DNA at
the −1 phosphate position.49–53,57,58 The use of a
single metal for phosphodiester bond breakage and
reformation parallels the mechanism of strand cleav-
age employed by ββα-Me and HUH nucleases.83
However, there is debate as towhether the twometals
found in the type II topoisomerase active site bind
simultaneously during DNA breakage and religation,
or if a single “dynamic” ion hops between the two
coordination sites at different stages of the reaction.
Support for the simultaneous two-metal mecha-
nism has derived from thiol-rescue studies,81,82 and
from a structure of S. cerevisiae Top2 captured in a
covalent product complex with a phosphorothiolated
DNA that was soaked with Zn2+ (Fig. 6a).53 By
comparison, the dynamic metal concept derives
from a number of type IIA topoisomerase∙DNA
complex structures that exhibit only a single metal
in either one position or the other.49–52,57,58 Howev-
er, each of these one-metal structures corresponds
to, or derives from, either drug-inhibited states of the
enzyme or complexes in which the DNA substrate is
not competent to support cleavage. For instance, in
all structures where the protein is bound to an
intercalative poison, or where the DNA is nicked at
the scissile position (as in the present TOP2A
model), only metal B is visible (Fig. 6b and c; Fig.
S3a). Alternatively, in the two topoisomerase∙DNA
complexes where the duplex backbone is intact andisomerase DNA-gate are quantized. This figure depicts the
d using the WHD of one protomer to reveal the relative
x groups. Cartoons depict just the three-helix bundles of the
r orientation. (a) Overview of the six juxtapositions: (1) no
) no DNA bound, C-gate closed [Escherichia coli gyrase
ILW)]; (3) DNA noncovalently bound, C-gate open [human
(4) DNA cleavage complex, C-gate closed [S. cerevisiae
closed, initial crystallization with drug bound [A. baumannii
opo IV cleavage complex bound to moxifloxacin (3FOF),
TN), the dione complex back soaked with EDTA (3KSA),
SB). The S. aureus gyrase noncovalent complex bound to
ciprofloxacin (2XCT) further map to this group]; (6) DNA
n TOP2B (3QX3)]. The red broken line indicates the
d closed C-gate states. The black broken line indicates the
d and free forms. (b) Binding of DNA causes the WHDs in
along the α3 helix (A′α3 helix in eukaryotic topoisomerase
by the apoenzyme [conformations 1 and 2 in (a)] and
3–5 in (a)]. A more extreme lateral shift is seen in the
face has been disrupted [conformation 6 in (a)]. (c) DNA
f the WHDs against each other. This rotation is quantized
d DNA [conformations 1 and 3 in (a)], a closed C-gate and
closed C-gate, covalently bound DNA, and drug binding
DNA cleavage complex, metals A and B bound nicked DNA complex, metal B only 
inhibitor exposed complex, metal A only intercalative poison bound complex, metal B only
(a) (b)
(c) (d)
A
B
A
B
A
B
A
B
A
B
A
B
A
B
A
B
Fig. 6. Comparison of metal occupancy between type IIA topoisomerase structures. (a) The structure of S. cerevisiae
topoisomerase II trapped in a cleavage intermediate by a phosphorothiolate suicide substrate has two metals, A and B,
bound in the active site (PDB 3L4K shown). (b) In structures solved with nicked substrates, only metal B is present,
as metal A binding requires coordination by the missing scissile phosphate (PDB 4FM9 shown). (c) Structures bound to
a type IIA topoisomerase poison bind only metal B, due to a shift of the phosphotyrosine out of the metal A binding site
(PDB 2XKK shown). (d) In structures bound to a non-intercalative drug (e.g., GSK29994), or where poison has been
removed following co-crystallization, only metal A is present. In these structures, residues in the DxD motif do not
form appropriate geometry for metal B coordination, due possibly to the retention of an altered DNA-gate state (cf. Fig. 5)
(PDB 2XCS shown).
118 Structure of DNA‐Bound Human TOP2Aa poison is not present—either because the protein is
bound to a non-intercalative drug (e.g., GSK29994) or
because the enzyme was first co-crystallized with a
poison before removal of the drug—only site A is
filled (Fig. 6d; Fig. S3b and c). The inability of
poisoned or nicked DNAs to support metal binding
at the A-position is readily understandable, as the
phosphate that coordinates this metal ion is either
shifted out of the active-site pocket (in drug-bound
states) or missing altogether. Similarly, the physical
impediment to metal binding at site B in the
GSK29994-associated or dione-pretreated com-
plexes coincides with a misalignment of the
coordinating residues in the DxD motif. This
alteration likely is coupled to the more extreme
WHD juxtaposition exhibited by these structures,
which matches that of other cleavage-impaired
drug-bound complexes (Fig. 5). These shifts mayalso explain why metal A remains present in the
enzyme active site even after EDTA treatment of the
dione-soaked crystals and why no other divalent
species appear following the addition of Mg2+: this
behavior suggests that the presence of drug
reconfigures the active site to tightly bind only a
single cofactor, which is sufficient to promote
religation in a nonideal crystalline environment
once drug is removed. Overall, the most parsimo-
nious interpretation of these data is that under
normal circumstances, two metals are present in the
active site during strand scission, whereas inhibitor
binding introduces new conformational constraints
that allow for occupancy of only a single metal ion.
This latter mode of action would be expected to
perturb the cleavage/religation equilibrium of the
enzyme, a well-established property of type IIA
topoisomerase poisons in general.
119Structure of DNA‐Bound Human TOP2ATogether, the observed pattern of coupled confor-
mational changes and DNA binding/cleavage status
not only supports the idea that a direct allosteric
connection exists between the state of the DNA-gate
and C-gate actuation but also highlights probable
substeps in the type IIA topoisomerase reaction
(Fig. 7; Movie S1). Prior to G-segment binding, the
DNA-gate can oscillate between dissociated and
associated conformers that are accompanied by a
dimerized (closed) C-gate (1).22,73–78 Occasionally,
when theDNA-gate adopts a closed configuration, the
C-gate can sample an open state (2), as is seen in A.
baumannii topo IV.52 We propose that binding of an
intact G-segment promotes the transition from this
“pre-engagement” state to an “engagement” configu-
ration (3), in which subunit-related TOPRIM andWHD
elements shift with respect to each other to both clamp
around DNA; this structural change simultaneouslyC gate open
C gate closed
G-segment DNA
D
2 ATP 
T-segment
DNA
1
4
3
A B A B
A B A B?
??
2
Pre-engagement Engagement
ATPase C-gate TOPRIM WHD
Fig. 7. Model relating DNA-gate status to C-gate dimeriza
topoisomerase reaction. Topoisomerase IIA dimers exist in an e
dissociated proteinaceous interfaces. Where double arrows a
likely weighted distribution of the two states. Prior to DNA bind
an open (2) C-gate. G-segment binding promotes the TOPRI
clamp around the DNA (3); this event may promote C-gate o
the T-segment, promote cleavage of the G-segment (5), favor
C-gate following its passage through the G-segment and rese
poisons and inhibitors such as GSK299943 perturb the DNA-g
for religation and may help maintain the C-gate in a closed co
between different ligand‐bound and/or free states are shown a
occupancies of the two metal-binding sites are also shown,
imaged. The lone question mark associated with site A, state
lack a scissile phosphate and, hence, may not capable of biimposes a WHD/WHD juxtaposition that modestly
destabilizes the C-gate and more readily allows for
separation (4), possibly by introducing strain into the
coiled-coil arms that link the DNA-gate and C-gate
together. ATP- and/or T-segment binding would
subsequently promote entry into a new physical
state—one that promotes DNA cleavage—by induc-
ing theWHDs to rotate with respect to each other and
bring the active-site tyrosines in-line to attackDNA (5).
This movement also would serve to relieve any strain
imposed by the engagement state and thereby
maintain C-gate closure. Resealing of the G-segment
would return the DNA‐gate to a conformation promot-
ing C‐gate dissociation and allow for T‐segment
release (6). Interestingly, our comparative studies
indicate that the binding of either small-molecule
poisons (which push apart the 3′ and 5′ ends of a
cleaved DNA) or other interfacial inhibitors thatapoenzyme
G-segment bound
P-T Cleavage complex
Drug stabilized 
cleavage complex
Inhibitors
5
6
7
A B A B
metal site
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metal site
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Cleavage
Drug inhibited complex
OR
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tion and metal occupancy in the context of the type IIA
quilibrium between different combinations of associated or
re shown, the relative thickness of the arrows denotes the
ing, DNA-gate closure can occur with either a closed (1) or
M domain, WHD, and tower domain of both protomers to
pening (4). ATP binding and capture of a second duplex,
ing C-gate closure. The T-segment exits through an open
aling of the cleaved DNA (6). Binding of topoisomerase II
ate interface to a more extended rotation that is impaired
nformation (7). Relative WHD displacements as observed
s cartoon cylinders and colored as per Fig. 5. The relative
with question marks denoting states that have yet to be
(4), reflects the fact that the DNAs found in these models
nding a metal ion accordingly.
120 Structure of DNA‐Bound Human TOP2Aassociate with the DNA-gate interface can promote
the formation of a more extreme rotation of the WHDs
with respect to each other (7). This action may help
such drugs trap the enzyme in an off-pathway state,
thereby impeding recovery to a religation-competent
form. Consistent with this model, the binding of
etoposide, which is substantially nonplanar compared
to its fluoroquinolone counterparts, promotes an even
morepronouncedWHD rotationandpartial separation
of the DNA-gate. An interesting secondary feature of
this model is that it suggests that the energy
landscape between conformational transitions con-
trolling DNA cleavage and gate opening is relatively
flat, with only subtle energetic differences needed to
shift from one structural intermediate to another.
Concluding remarks
In summary, this work presents the first structure
of the DNA binding and cleavage core of human
TOP2A bound to DNA. Consideration of the model in
light of existing structures of homologous enzymes
has enabled us to better understand several
important facets of type IIA topoisomerase mecha-
nism and inhibition. In particular, we find that the two
WHDs of a topoisomerase dimer, which form part of
the region responsible for cleaving and opening DNA
(the DNA-gate), adopt only a small set of positional
configurations with respect to each other. These
quantized conformations appear to couple DNA
cleavage status with the allosteric control of in-
teractions at a distal subunit interface, the C-gate,
which sits more than 50 Å away from the enzyme
active site (Movie S1). Anti-topoisomerase agents
that bind within the DNA-gate appear to subvert
these movements, altering the position and occu-
pancy of reactive elements to either impede or
stabilize cleavage and religation events. Compari-
sons of our model with an etoposide-inhibited state
of the second human type IIA topoisomerase,
TOP2B, not only highlight the similarities between
the two isoforms but also suggest avenues for
promoting epipodophyllotoxin selectivity that might
be of use in countering secondary malignancies.
Future efforts aimed at imaging additional interme-
diates and drug-bound states will be needed to
investigate these ideas further.
Materials and Methods
A truncation of the DNA binding and cleavage core from
the human gene TOP2A23 (residues 431–1193, Fig. 1a)
was cloned into a GAL1-based yeast shuttle vector, in
frame with an N-terminal tobacco etch virus protease-
cleavable His6-MBP tag. Protein was expressed in S.
cerevisiae strain BCY123 (MATα pep3::HIS3 prb1::LEU2
bar1::HISG lys2::GAL1/10-GAL4 can1 ade2 trp1 ura3 his3
leu2-3,112,84 originally from the laboratory of R. Kornberg)
grown in CSM-Ura- media with a 2% lactic acid and 1.5%glycerol carbon source at 30 °C. Overexpression was
induced by the addition of 2% galactose at A600 = 0.9. Six
hours after induction, cells were centrifuged (4500 rpm,
4 °C, 15 min), resuspended in 1 mM EDTA and 250 mM
NaCl (1 mL per liter of liquid culture), and flash frozen
dropwise in liquid nitrogen.
For purification, frozen cells were first lysed under
liquid nitrogen by grinding with a mortar and pestle, and
the resultant powder was thawed and resuspended in
20 mM Tris–HCl (pH 8.5), 300 mM KCl, 20 mM imidaz-
ole, and 10% glycerol (20 mL per liter of liquid culture)
supplemented with protease inhibitors (1 mM PMSF,
2.34 μM leupeptin, and 1.45 μM pepstatin). Lysate was
clarified by centrifugation (15,000 rpm, 4 °C, 20 min) and
run over a nickel-chelating Sepharose column (GE) at
4 °C. Following a column wash in resuspension buffer,
tagged TOP2A was eluted stepwise with resuspension
buffer plus 200 mM imidazole. Eluted protein was
concentrated using a 100‐kDa cutoff centrifugal filter
(Amicon), buffer exchanged with resuspension buffer,
and then incubated overnight with His-tagged tobacco
etch virus protease at 4 °C.85 Protease and uncleaved
protein were removed by running over a second nickel
column, and the eluted cleaved protein was run over a
gel‐filtration column (S300, GE) equilibrated in 500 mM
KCl, 20 mM Tris–HCl (pH 7.9), and 10% glycerol. Purity
was estimated by SDS-PAGE, and peak fractions were
combined and concentrated to ~15.8 mg/mL protein
using a 100‐kDa cutoff filter.
Oligonucleotides were ordered from Integrated DNA
Technologies. After receipt, DNAs were purified by
urea-formamide PAGE, resuspended in 200 mM KCl
and 10 mM Tris–HCl (pH 7.9), and annealed to form a
13‐bp duplex with a complementary four-base, 5′ over-
hang. This construct results in the formation of a doubly
nicked, 30‐bp DNA substrate (Fig. 1b) when bound to a
TOP2A homodimer. DNA and protein were combined in a
1.1:1 molar ratio of DNA 30mer:TOP2A dimer and dialyzed
stepwise against 20 mM Tris–HCl (pH 7.9) and 10 mM
MgCl2 and decreasing concentrations of KCl (500 mM,
250 mM, 100 mM). Dialysis ran over the course of 16 h at
4 °C to a final condition of 20 mM Tris–HCl (pH 7.9),
10 mM MgCl2, and 100 mM KCl using a 1000‐Da cutoff
mini-capillary dialyzer (Harvard Apparatus). Crystals grew
within a day of setting hanging drops by mixing 150 nL of a
5‐mg/mL protein/DNA sample with 150 nL 10% (w/v)
polyethylene glycol 3000, 100 mM Na-cacodylate
(pH 6.5), and 200 mM MgCl2 solution at 18 °C. Crystals
were looped and cryoprotected with well solution plus 29%
glycerol before being flash frozen in liquid nitrogen.
Diffraction experiments were performed at the 8.3.1
beamline of the Advanced Light Source at Lawrence
Berkeley National Laboratory.86 Data were collected on an
ADSCQ210 CCD detector using a wavelength of 1.1159 Å,
and crystals were maintained at 100 K by a gaseous N2
cyrostat. Data were integrated and scaled using HKL200087
and reduced using CCP4 software.88 Based on BLAST
analysis of type IIA topoisomerase homologs at the time (the
human TOP2B model had not yet been published),89,90 a
molecular replacement search model comprising the DNA-
gate (residues 431–1014 and 1165–1189, TOP2A number-
ing) of a single protomer bound to half the DNA substrate but
excluding the α-helical arms and C-gate was prepared from
the crystal structure of the yeast topoisomerase II DNA
binding and cleavage core bound toDNA [residues 419–989
121Structure of DNA‐Bound Human TOP2Aand 1153–1177, Protein Data Bank (PDB) ID: 2RGR].50
Side‐chain lengths in the search model were reduced to the
last common atom using CHAINSAW.91 From this model,
PHASER was used to find a positional solution and
determine initial phases;92 molecular replacement was
performed with the same initial search model, but without
DNA, and yielded an identical solution with strong positive
difference density confirming that the DNA substrate was
present. A secondmolecular replacement search using only
the globular domains of the C‐gate was performed against
the first solution to determine placement of this region, again
using the yeast topoisomerase II DNA structure as a search
model (residues 1029–1136, PDB ID: 2RGR). The resultant
asymmetric unit consists of a single protomer and half the
DNA substrate; the protein dimer is generated by a
crystallographic 2-fold axis. After a round of rigid‐body
refinement using PHENIX,93 the model was improved by
building inCoot94 and refinement inPHENIXusing individual
site refinement, individual ADP refinement, and TLS. The
TLS Server95,96 was used to inform decisions for TLS
groups. The final model included the entire DNA substrate
and the entire protein construct, excluding residues 1092–
1124, the N-terminus (residues 431–432), and the C-
terminus (residues 1190–1193). Model validation was
performed by MolProbity;56 comparisons between different
topoisomerase models were conducted using PyMOL.97
Accession numbers
Structure factors and atomic coordinates have been
deposited in the PDB with accession number 4FM9.Acknowledgements
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